What is the equity of Diaceutics this year?
Diaceutics has equity of 31.42 M GBP this year.
Diaceutics Equity 2024
Diaceutics Equity
31.42 M GBP
Ticker
DXRX.L
ISIN
GB00BJQTGV64
WKN
A2PF80
In 2024, Diaceutics's equity was 31.42 M GBP, a -26.09% increase from the 42.51 M GBP equity in the previous year.
Diaceutics Aktienanalyse
What does Diaceutics do?
Diaceutics PLC is a consulting company specializing in optimizing diagnostic and treatment solutions for patients with serious and complex diseases. It was founded in 2005 by Peter Keeling in Belfast, Northern Ireland, and is now headquartered in London, UK. The company is listed on the London Stock Exchange and has offices in Europe, Asia, North America, and Australia. The business model of Diaceutics is based on the increasing number of personalized medicines on the market, targeting specific genetic markers to enable more accurate diagnosis and treatment. The company specializes in analyzing laboratory data to help doctors and pharmaceutical companies identify the specific tests needed for treating individual patients. It also offers a variety of services to optimize the use of tests in patient care. Diaceutics operates in three divisions: Diagnostic Services, Data and Analytics Services, and Strategy and Implementation Services. Diagnostic Services include optimizing diagnostic tests and identifying patient populations that would benefit from a particular treatment. Data and Analytics Services involve setting up data and analytics platforms to gain insights into the use of diagnostic tests in clinical practice. Strategy and Implementation Services support pharmaceutical companies in conducting campaigns to promote the use of diagnostic tests and increase the availability of personalized medicines. Diaceutics' products and services also include Diagnostic Insights products, providing insights into the use of diagnostic tests in various therapy areas. These insights help pharmaceutical companies optimize their personalization strategies and enhance the effectiveness of their medicines. The company also offers diagnostic programs aimed at promoting the use of diagnostic tests in clinical practice and eliminating barriers to the use of personalized medicines. Diaceutics has established partnerships with many of the world's leading diagnostic and pharmaceutical companies and also provides consulting services to support them in developing personalization strategies. Its clients include both pharmaceutical and diagnostic companies. Overall, Diaceutics has become a leading provider of personalized healthcare solutions. It occupies a unique position in the market by focusing on the intersection of diagnostics and therapy and being able to offer a wide range of products and services. Given the rapid progress in personalized medicine, Diaceutics will continue to play a significant role in optimizing diagnosis and treatment strategies and providing better care for patients. Diaceutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Diaceutics's Equity
Diaceutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Diaceutics's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Diaceutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Diaceutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Diaceutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Diaceutics stock
What was the equity of Diaceutics compared to the previous year?
The equity of Diaceutics has increased/decreased by -26.09% decreased compared to the previous year.
What impact does a high equity have on investors of Diaceutics?
A high equity is advantageous for investors of Diaceutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Diaceutics?
A low equity can be a risk for investors of Diaceutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Diaceutics affect the company?
An increase in equity of Diaceutics can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Diaceutics affect the company?
A reduction in equity of Diaceutics can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Diaceutics?
Some factors that can affect the equity of Diaceutics include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Diaceutics so important for investors?
The equity of Diaceutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Diaceutics take to change the equity?
To change equity, Diaceutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Diaceutics pay?
Over the past 12 months, Diaceutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Diaceutics is expected to pay a dividend of 0 GBP.
What is the dividend yield of Diaceutics?
The current dividend yield of Diaceutics is .
When does Diaceutics pay dividends?
Diaceutics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Diaceutics?
Diaceutics paid dividends every year for the past 0 years.
What is the dividend of Diaceutics?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is Diaceutics located?
Diaceutics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Diaceutics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Diaceutics from 10/6/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/6/2024.
When did Diaceutics pay the last dividend?
The last dividend was paid out on 10/6/2024.
What was the dividend of Diaceutics in the year 2023?
In the year 2023, Diaceutics distributed 0 GBP as dividends.
In which currency does Diaceutics pay out the dividend?
The dividends of Diaceutics are distributed in GBP.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Diaceutics
Our stock analysis for Diaceutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Diaceutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
